Fifty 410 Review

Fifty 410 — Provider Profile

Overview

Fifty 410 (operated by Aspen Aesthetics LLC) is a telehealth platform offering compounded GLP-1 medications with two features that stand out in the market: no credit card required until after a provider approves your consultation, and the most detailed dose-specific tirzepatide pricing available among compounded providers. The platform also has a notably large independent review base — 4,381 Trustpilot reviews at 4.8/5 — making it more independently validated than most competitors in this space.

The consultation process is designed to reduce commitment friction: patients complete a five-minute online questionnaire, pay nothing until a licensed provider approves them, and receive all medication for multi-month plans shipped at once.

April 2026 context: Fifty 410 prescribes compounded semaglutide and compounded tirzepatide only — no brand-name FDA-approved options are offered. Compounded GLP-1s are not FDA-approved. The FDA has been actively taking enforcement action against certain compounders and continues to pressure the sector. The no-credit-card-until-approved model is patient-friendly, but patients should understand the regulatory environment before starting any compounded GLP-1 program.

Medications Offered

• Compounded semaglutide injectable — Not FDA-approved
• Compounded tirzepatide injectable — Starter and high-dose options available; Not FDA-approved
• Additional injectables: NAD+, Sermorelin, Glutathione, Methylene Blue
• No brand-name FDA-approved options

Tirzepatide is available in multiple dose configurations through partner pharmacy BPI. Prescription sales are final — patients should review the refund policy before enrolling.

Pricing

Semaglutide

The 3-month semaglutide plan at $99/mo equivalent is among the most affordable multi-month rates available for compounded semaglutide.

Tirzepatide

Pricing includes: licensed provider consultation, free overnight or 2-day refrigerated shipping. No subscription. No membership fees. No auto-charges. Payment accepted via major credit cards, Afterpay, and Affirm.

Multi-month plans ship all medication at once — patients receive their full supply upfront rather than waiting for monthly refills.

States Served

All supported U.S. states. Some states require a video or phone consultation before the provider can approve treatment. Confirm your state's requirements during the intake process.

Insurance

• Insurance: Not accepted
• FSA/HSA: Accepted

Consultation Process

1. Complete an online health questionnaire — approximately 5 minutes; no credit card required
2. Licensed provider reviews submission within 24–48 hours
3. If approved, a payment link is sent — no charge until approval
4. Medication ships within 2–6 business days with free overnight or 2-day refrigerated shipping
5. Multi-month plans ship complete supply in a single shipment

Patients can get a clinical evaluation with no financial commitment. If not approved, there is no charge.

Pros

• No credit card required until after provider approval — genuine risk reduction for patients
• Multi-month supply ships all at once — no monthly refill anxiety or supply disruptions
• $99/mo equivalent on 3-month semaglutide plan — one of the most affordable rates in the compounded market
• Most detailed dose-specific tirzepatide pricing in the peer group — patients can calculate total titration cost before committing
• Outstanding independent review record: 4.8/5 on Trustpilot across 4,381 reviews (the largest review sample in this group)
• No subscriptions, no auto-charges, no membership fees
• FSA/HSA accepted
• Claims 100,000+ customers

Cons

• All prescription sales are final — refund window is limited; review the policy carefully before ordering
• Binding arbitration clause and class-action waiver (Texas law) — standard in this sector but worth noting
• All medications are compounded — no FDA-approved option available
• Compounded GLP-1s face active FDA enforcement pressure; supply and legal landscape can change
• Some states require video/phone consultation before approval (adds friction for fully async-seeking patients)
• Monthly tirzepatide at $299/mo is not as competitively priced as the bundle options suggest

Best For

Patients who want to evaluate their options before making any financial commitment. The no-credit-card-until-approved model is the most patient-protective intake process among compounded GLP-1 providers. Patients can get a full clinical evaluation — and find out whether they qualify — without giving payment information upfront.

The large Trustpilot review base (4,381 reviews at 4.8/5) also makes Fifty 410 one of the most independently validated options in this group. Reviews can be manufactured, but 4,381 is a sample size large enough to be meaningful signal.

For patients comparing tirzepatide costs across providers, the dose-specific pricing tables let you calculate what a full titration will actually cost — rather than discovering the price increases as you move up in dose.

Not ideal for: Patients who need medication quickly (the 2–6 business day shipping timeline after approval is reasonable but not same-week), or patients who want brand-name FDA-approved medications.

Editorial Verdict

Two aspects of Fifty 410 directly benefit patients making purchasing decisions: no financial commitment until after approval, and the most transparent tirzepatide pricing in its peer group.

Most telehealth GLP-1 providers require payment upfront before clinical review. Fifty 410 reverses that — the patient completes the questionnaire, the provider reviews it, and the payment link only arrives if approved. That structure means patients who are declined pay nothing. It also means the approval decision is clinical rather than financial.

The dose-specific tirzepatide pricing table is also notable. Most providers publish a starting price and obscure how costs change at higher doses. Fifty 410 publishes costs at every dose level through 15mg — patients can calculate their total titration cost before ordering.

The 4,381 Trustpilot reviews at 4.8/5 are unusual for a compounded GLP-1 provider. This is not a guarantee of quality, but it is meaningful independent signal in a market where many providers have thin or absent public review histories.

The standard caveats apply: all medications are compounded, not FDA-approved, and the FDA is actively pressuring the compounding sector as of April 2026.

Bottom line as of April 2026: Fifty 410 is one of the more patient-friendly intake experiences in the compounded GLP-1 market. For patients doing careful research before committing, the combination of no-upfront payment and transparent dose-level pricing is genuinely useful.

Related Content

• Best GLP-1 Weight Loss Programs 2026 — All providers ranked
• GLP-1 Compounding Pharmacies: What Patients Need to Know — Full regulatory context
• GLP-1 Cost & Insurance FAQ — What you'll actually pay